Evidence map›Paper›PMID 32847594›Full record

ReviewJournal of translational medicine2020

The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19.

Yi Xu, David J Baylink, Chien-Shing Chen, Mark E Reeves, Jeffrey Xiao, Curtis Lacy, Eric Lau, Huynh Cao

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Journal of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05630339 (Efficacy and Security of the Magnesium and Vitamin D Combination as Adjuvant Treatment of Post-COVID Syndrome. A Randomised Double-blind Clinical Trial), which is not on this map. Cited by 81 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 3 pooled it
18.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05630339 nacompletednot on this mapstarted 2022, after this paper: background citation

Efficacy and Security of the Magnesium and Vitamin D Combination as Adjuvant Treatment of Post-COVID Syndrome. A Randomised Double-blind Clinical Trial

TypeinterventionalSponsorCoordinación de Investigación en Salud, MexicoRan2022 to 2023Enrolled150ConditionsPost-COVID-19 Syndrome, Long COVID, Vitamin D Deficiency, Magnesium DeficiencyArmsMagnesium chloride, Vitamin D, Inert placebo
3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 3 syntheses or guidelines pooled it, 189 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Low vitamin D status is associated with coronavirus disease 2019 outcomes: a systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Pooled it
  4. Trial
  5. Review
  6. Ambient Air Pollution and COVID-19 in California.Research report (Health Effects Institute) · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. COVID-19 and the Nervous System from a Cuban Experience.Behavioral sciences (Basel, Switzerland) · 2023
    Review
  19. Review
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yi XuDivision of Hematology and Oncology, Department of Medicine, Loma Linda University, Loma Linda, California, USA. dyxu@llu.edu.ORCID 0000-0002-6917-184X
David J BaylinkDivision of Regenerative Medicine, Department of Medicine, Loma Linda University, Loma Linda, California, USA.
Chien-Shing ChenDivision of Hematology and Oncology, Department of Medicine, Loma Linda University, Loma Linda, California, USA.
Mark E ReevesDivision of Hematology and Oncology, Department of Medicine, Loma Linda University, Loma Linda, California, USA.
Jeffrey XiaoDivision of Regenerative Medicine, Department of Medicine, Loma Linda University, Loma Linda, California, USA.
Curtis LacyDivision of Hematology and Oncology, Department of Medicine, Loma Linda University, Loma Linda, California, USA.
Eric LauDivision of Hematology and Oncology, Department of Medicine, Loma Linda University, Loma Linda, California, USA.
Huynh CaoDivision of Hematology and Oncology, Department of Medicine, Loma Linda University, Loma Linda, California, USA.
Loma Linda University · US

Funding

Loma Linda University GRASP2020Loma Linda University RIG
6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has led to a declaration of a Public Health Emergency of International Concern by the World Health Organization. As of May 18, 2020, there have been more than 4.7 million cases and over 316,000 deaths worldwide. COVID-19 is caused by a highly infectious novel coronavirus known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), leading to an acute infectious disease with mild-to-severe clinical symptoms such as flu-like symptoms, fever, headache, dry cough, muscle pain, loss of smell and taste, increased shortness of breath, bilateral viral pneumonia, conjunctivitis, acute respiratory distress syndromes, respiratory failure, cytokine release syndrome (CRS), sepsis, etc. While physicians and scientists have yet to discover a treatment, it is imperative that we urgently address 2 questions: how to prevent infection in immunologically naive individuals and how to treat severe symptoms such as CRS, acute respiratory failure, and the loss of somatosensation. Previous studies from the 1918 influenza pandemic have suggested vitamin D's non-classical role in reducing lethal pneumonia and case fatality rates. Recent clinical trials also reported that vitamin D supplementation can reduce incidence of acute respiratory infection and the severity of respiratory tract diseases in adults and children. According to our literature search, there are no similar findings of clinical trials that have been published as of July 1st, 2020, in relation to the supplementation of vitamin D in the potential prevention and treatment for COVID-19. In this review, we summarize the potential role of vitamin D extra-renal metabolism in the prevention and treatment of the SARS-CoV-2 infection, helping to bring us slightly closer to fulfilling that goal. We will focus on 3 major topics here: 1. Vitamin D might aid in preventing SARS-CoV-2 infection: Vitamin D: Overview of Renal and Extra-renal metabolism and regulation. Vitamin D: Overview of molecular mechanism and multifaceted functions beyond skeletal homeostasis. Vitamin D: Overview of local immunomodulation in human infectious diseases. Anti-viral infection. Anti-malaria and anti-systemic lupus erythematosus (SLE). 2. Vitamin D might act as a strong immunosuppressant inhibiting cytokine release syndrome in COVID-19: Vitamin D: Suppression of key pro-inflammatory pathways including nuclear factor kappa B (NF-kB), interleukin-6 (IL-6), and tumor necrosis factor (TNF). 3. Vitamin D might prevent loss of neural sensation in COVID-19 by stimulating expression of neurotrophins like Nerve Growth Factor (NGF): Vitamin D: Induction of key neurotrophic factors. .

Indexed as

BetacoronavirusBrainChemopreventionCoronavirus InfectionsCOVID-19Dietary SupplementsHumansImmune SystemImmunomodulationNeuroprotectionNeuroprotective AgentsPandemicsPneumonia, ViralSARS-CoV-2Vitamin DVitamin D DeficiencyNeuroprotective AgentsVitamin D1,25(OH)2D325(OH)DCoronavirusCOVID-19Extra-renalIL-6ImmunomodulationInfectionMetabolismNF-kBNGFTNFVitamin D

Identifiers

PMID32847594
PMCPMC7447609
OpenAlexW3080788953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.